The
European Medicines Agency has issued a new draft document, with the lengthy title of
“Questions and answers on implementation of risk based prevention of cross contamination
in production and ‘Guideline on setting health based exposure limits for use in
risk identification in the manufacture of different medicinal products in
shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012).”
The
document deals with highly hazardous products are those that can cause serious
adverse effects at low doses and that therefore would benefit from a full
toxicological assessment in order to derive a safe Health Based Exposure Limits.
A health based exposure limit is a limit (permitted daily exposure (PDE) or
equivalent) at which a product is regarded to be safe in humans. It can be
based on either clinical dose or non-clinical safety data, depending on which
would give the lower exposure limit.
Such
products are:
- Genotoxic (specifically mutagenic) compounds that are known to be, or highly likely to be, carcinogenic to humans. Compounds of this group are easily identifiable, since genotoxicity would be related to the pharmacology, e.g. as DNA alkylating cytostatics, and their use is usually restricted to oncology indications with respective warning statements in the Summary of Product Characteristics.
- Compounds that can produce reproductive and/or developmental effects at low dosages, for example where evidence exists of such effects being caused by a clinical dose of <10 mg/day (veterinary dose equivalent 0.2 mg/kg/day) or dosages in animal studies of ≤1 mg/kg/day.
- Compounds that can produce serious target organ toxicity or other significant adverse effects at low doses, for example where evidence exists of such effects being caused by a clinical dose of <10 mg/day (veterinary dose equivalent 0.2 mg/kg/day) or dosages in animal studies of ≤1 mg/kg/day.
- Compounds with a high pharmacological potency i.e. recommended daily dose of <1 mg (veterinary dose equivalent 0.02 mg/kg)
Compounds
with a high sensitising potential.
Posted by Dr. Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources